Form 4: Exelixis Executive Patrick J. Haley Acquires Shares Through Performance-Based Vesting

Exelixis EVP, Commercial, Patrick J. Haley, acquired 123,750 shares of common stock due to the vesting of performance-based restricted stock units, while also disposing of shares to cover tax obligations.

Summary

• Patrick J. Haley, EVP, Commercial at Exelixis, acquired 123,750 shares of common stock on January 16, 2025, due to the vesting of performance-based restricted stock units (PSUs).
• The vesting was triggered by the Compensation Committee's certification that certain performance criteria had been met.
• The PSU award, granted on March 4, 2022, allowed for vesting of up to 175% of the target shares based on performance.
• 50% of the achieved shares vested immediately on January 16, 2025, and the remaining 50% will vest on February 15, 2026, subject to continued service.
• Additionally, 27,563 shares were disposed of to cover tax obligations related to the vesting of the PSU.
• Haley also holds 272,498 shares of Exelixis common stock that will be issued upon the vesting of restricted stock units (RSUs).
• Haley's spouse holds 23,539 shares and 10,648 shares are held in a 401(k) plan.

Sentiment

Score: 7

Explanation: The document reflects a positive event (vesting of shares due to performance) but also includes a negative (disposal of shares for tax), resulting in a moderately positive sentiment.

Positives

• The vesting of performance-based restricted stock units indicates that the company has met certain performance criteria.
• Patrick J. Haley's increased shareholding aligns his interests with those of the company and its shareholders.
• The vesting of the PSU demonstrates the company's commitment to incentivizing its executives based on performance.

Negatives

• The disposal of 27,563 shares to cover tax obligations resulted in a reduction of Haley's overall shareholding.

Risks

• The future vesting of the remaining 50% of the achieved shares is contingent on Haley's continued service with the company.
• The value of the shares is subject to market fluctuations, which could impact the overall value of Haley's holdings.

Future Outlook

50% of the achieved shares will vest on February 15, 2026, subject to the Reporting Person's continuous service through that date.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It reflects the company's compensation structure and the alignment of executive interests with shareholder value.

Comparison to Industry Standards

• Performance-based equity awards are a common practice in the biotechnology industry to incentivize executives and align their interests with company performance.
• The vesting schedule of the PSU, with a portion vesting upon performance achievement and the remainder vesting over time, is a typical structure used by companies like Exelixis.
• Companies such as Gilead Sciences, Amgen, and Biogen also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the vesting of performance-based shares as a positive sign of the company's performance.
• The transaction has a neutral impact on employees, customers, suppliers, and creditors.

Next Steps

• The remaining 50% of the achieved shares will vest on February 15, 2026, subject to Patrick J. Haley's continued service.

Key Dates

Keywords

Exelixis, stock, vesting, performance-based, restricted stock units, PSU, shares, executive, insider trading, equity